Amoy Diagnostics

OverviewSuggest Edit

Amoy Diagnostics (AmoyDx, 艾德生物) is a company that provides molecular diagnostic products and services for oncology precision medicine. It offers test kits, including NGS (next-generation sequencing), PCR (polymerase chain reaction), and FISH (fluorescence in situ hybridization) assays, as well as DNA and RNA extraction kits. The company serves healthcare providers, academic institutions, and pharmaceutical businesses.

TypePublic
Founded2008
HQXiamen, CN
Websiteamoydiagnostics.com

Latest Updates

Employees (est.) (Dec 2019)654(+21%)
Revenue (FY, 2021)¥903.9 M(+26%)
Share Price (Aug 2022)¥26.7(-2%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Amoy Diagnostics

Li-mou Zheng

Li-mou Zheng

Founder and CEO

Amoy Diagnostics Office Locations

Amoy Diagnostics has an office in Xiamen
Xiamen, CN (HQ)
39 Dingshan Road, Haicang District
Show all (1)

Amoy Diagnostics Financials and Metrics

Amoy Diagnostics Revenue

Embed Graph
View revenue for all periods
Amoy Diagnostics's revenue was reported to be ¥903.95 m in FY, 2021
CNY

Revenue (Q1, 2022)

205.4m

Gross profit (Q1, 2022)

170.7m

Gross profit margin (Q1, 2022), %

83.1%

Net income (Q1, 2022)

53.3m

EBITDA (Q1, 2022)

55.7m

EBIT (Q1, 2022)

58.3m

Market capitalization (2-Aug-2022)

5.9b

Closing stock price (2-Aug-2022)

26.7

Cash (31-Mar-2022)

441.8m

EV

5.5b
Amoy Diagnostics's current market capitalization is ¥5.9 b.
Annual
CNYFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

435.5m573.8m719.9m903.9m

Cost of goods sold

(39.4m)(55.7m)(94.9m)(143.3m)

Gross profit

396.9m518.9m630.1m769.6m

Gross profit Margin, %

91%90%88%85%
Quarterly
CNYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

118.8m145.3m145.7m90.3m280.0m111.8m173.0m219.8m250.1m205.4m

Cost of goods sold

(10.6m)(14.4m)(14.9m)(11.6m)(33.6m)(15.8m)(30.3m)(31.8m)(41.7m)(34.7m)

Gross profit

108.2m131.3m130.4m78.7m248.1m94.4m142.7m192.2m204.2m170.7m

Gross profit Margin, %

91%90%90%87%89%84%82%87%82%83%
Annual
CNYFY, 2018FY, 2019FY, 2020FY, 2021

Cash

198.2m498.4m361.6m402.9m

Accounts Receivable

188.9m233.1m316.5m428.8m

Prepaid Expenses

1.1m14.2m1.7m9.1m

Inventories

14.1m17.2m21.4m32.3m
Quarterly
CNYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

241.0m252.9m262.0m425.7m362.4m442.8m376.2m392.1m346.6m441.8m

Accounts Receivable

198.5m213.3m220.4m207.0m265.0m272.1m308.5m353.7m403.9m447.1m

Prepaid Expenses

869.0k4.0m3.3m12.7m2.0m3.1m2.8m6.6m6.8m1.8m

Inventories

17.4m17.3m18.2m27.1m43.2m36.4m26.2m36.5m35.7m30.4m
Annual
CNYFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

126.7m135.5m180.3m239.0m

Depreciation and Amortization

19.7m24.2m27.3m36.4m

Inventories

(4.4m)(3.1m)(4.3m)(10.8m)

Accounts Payable

7.0m54.1m78.0m19.2m
Quarterly
CNYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

78.2m80.8m80.8m111.3m

Depreciation and Amortization

11.8m13.1m13.1m16.8m

Inventories

(3.3m)(25.9m)(25.9m)(13.3m)

Accounts Payable

23.6m47.4m47.4m15.5m
CNYFY, 2018

Revenue/Employee

805.0k

Financial Leverage

1.1 x
Show all financial metrics

Amoy Diagnostics Operating Metrics

FY, 2017H1, 2018FY, 2018H1, 2019FY, 2019H1, 2020

Medical Institutions Covered

300300400400500500

Medical Device Registration Certificates

181921222222

Patents (Domestic)

212429283234

Patents (Foreign)

333

Amoy Diagnostics Acquisitions / Subsidiaries

Company NameDateDeal Size
Shanghai Shawei Biotechnology Co., Ltd.

Amoy Diagnostics Revenue Breakdown

Embed Graph

Amoy Diagnostics revenue breakdown by business segment: 76.2% from REAGENT INCOME, 16.9% from TESTING SERVICE REVENUE, 5.9% from DRUG CLINICAL RESEARCH SERVICE and 1.0% from Other

Amoy Diagnostics revenue breakdown by geographic segment: 88.5% from CHINA (PEOPLES REPUBLIC) and 11.5% from REST OF WORLD

Amoy Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Amoy Diagnostics Online and Social Media Presence

Embed Graph

Amoy Diagnostics News and Updates

AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market

Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib for China market. The CDx test is based on AmoyDx's industry-leading PCR platform. …

喜讯频传:艾德生物再获两项国家级认定

近日,工业和信息化部发布第二批专精特新“小巨人”企业名单,艾德生物被认定为第二批专精特新“小巨人”企业

AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide

Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) signed a collaborative memorandum with AstraZeneca in the third China International Import Expo.

Amoy Diagnostics Frequently Asked Questions

  • When was Amoy Diagnostics founded?

    Amoy Diagnostics was founded in 2008.

  • Who are Amoy Diagnostics key executives?

    Amoy Diagnostics's key executives are Li-mou Zheng.

  • How many employees does Amoy Diagnostics have?

    Amoy Diagnostics has 654 employees.

  • What is Amoy Diagnostics revenue?

    Latest Amoy Diagnostics annual revenue is ¥903.9 m.

  • What is Amoy Diagnostics revenue per employee?

    Latest Amoy Diagnostics revenue per employee is ¥1.4 m.

  • Who are Amoy Diagnostics competitors?

    Competitors of Amoy Diagnostics include MGI, ZAI Lab and Thermo Fisher Scientific.

  • Where is Amoy Diagnostics headquarters?

    Amoy Diagnostics headquarters is located at 39 Dingshan Road, Haicang District, Xiamen.

  • Where are Amoy Diagnostics offices?

    Amoy Diagnostics has an office in Xiamen.

  • How many offices does Amoy Diagnostics have?

    Amoy Diagnostics has 1 office.